Form 4: Director Eric Benevich Acquires ATYR Pharma Stock Options

Eric Benevich, a Director at ATYR Pharma Inc., has acquired 50,000 stock options, signaling a potential long-term commitment to the company.

Summary

• Eric Benevich, a Director of ATYR Pharma Inc., was granted 50,000 stock options on May 11, 2026.
• These options have an exercise price of $0.95 and are exercisable starting May 11, 2026, with an expiration date of May 11, 2036.
• The options vest in full on the earlier of May 11, 2027, or the company's 2027 Annual Meeting of Stockholders, contingent upon continued service on the Board of Directors.
• Following this transaction, Benevich beneficially owns 50,000 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it indicates director confidence and alignment of interests, but it does not represent new financial performance data.

Positives

• Director Eric Benevich has acquired a significant number of stock options, indicating confidence in the company's future prospects.
• The stock options are exercisable, providing a potential future financial benefit to the director.
• The grant of options aligns the director's interests with those of shareholders through potential equity appreciation.

Negatives

• The filing does not disclose any negative financial performance or operational setbacks.
• No immediate financial cost or dilution to existing shareholders is apparent from this option grant.

Risks

• The vesting of the options is contingent on continued service, meaning the director could forfeit them if they leave the board before the vesting date.
• The value of the options is subject to the future stock price performance of ATYR Pharma Inc., which carries inherent market risk.
• The exercise price of $0.95 means the options will only be profitable if the stock price exceeds this level.

Future Outlook

The grant of stock options with a long expiration date and a vesting schedule tied to continued service suggests a positive long-term outlook from the director's perspective. The options are exercisable and vest in full by May 11, 2027, or the 2027 Annual Meeting, indicating management's expectation of sustained operations and potential stock price appreciation.

Management Comments

• The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors to incentivize long-term performance and align executive interests with shareholder value, especially for companies in development stages.

Stakeholder Impact

• Shareholders: The grant of options to a director aligns their interests with shareholders, potentially leading to decisions that benefit long-term stock value. However, it does not immediately impact share price or provide new financial information.
• Employees: The option grant to a director may indirectly signal confidence in the company's future, which can positively affect employee morale.
• Management: The transaction is a standard part of director compensation and does not represent a change in management structure.

Next Steps

• Eric Benevich is expected to continue his service on the ATYR Pharma Inc. Board of Directors.
• The stock options will vest on May 11, 2027, or at the 2027 Annual Meeting, whichever comes first.
• The options can be exercised anytime between their vesting date and the expiration date of May 11, 2036.

Key Dates

Keywords

ATYR Pharma, Form 4, Stock Options, Insider Trading, Director Compensation, Beneficial Ownership, Securities Exchange Act, Equity Grant